Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06062069 · ClinicalTrials.gov registry record · Phase 2
A Study of CT-868 in Type 1 Diabetes Mellitus
A Phase 2 study, sponsored by Carmot Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 111
- Enrollment target
NCT06062069 is a Phase 2 study that has completed, run by Carmot Therapeutics. The registered enrollment target is 111 participants.
The verdict
NCT06062069, a Phase 2 study, has completed, sponsored by Carmot Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 111 participants
- Enrollment target
Study Summary
This study will evaluate the changes in glycemic control in overweight and obese adults with Type 1 Diabetes Mellitus after receiving CT-868 for 16 weeks. The effectiveness and safety of CT-868 will be compared to placebo. All participants will continue with their standard diabetes care using either an insulin pump (CSII) or multiple daily injections (MDI). Alongside their designated treatment, participants will receive guidance on managing their diabetes, including monitoring blood glucose levels and diet and exercise recommendations. Treatment assignments, either CT-868 plus insulin or placebo plus insulin will be randomly determined.
Interventions
- DRUG CT-868
- DEVICE CT-868 Pen Injector
- DRUG CT-868 Pen Injector, Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2023-10-19 |
| Est. Completion | 2025-07-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06062069
The ClinicalTrials.gov registry entry for NCT06062069 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Carmot Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which CT-868 is the first listed.
NCT06062069 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06062069 about?
NCT06062069 is a clinical study titled "A Study of CT-868 in Type 1 Diabetes Mellitus". This study will evaluate the changes in glycemic control in overweight and obese adults with Type 1 Diabetes Mellitus after receiving CT-868 for 16 weeks. The effectiveness and safety of CT-868 will be compared to placebo. All participants will continue with their standard diabetes care using either...
What is the current status of trial NCT06062069?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 111 participants. The study started on 2023-10-19. Estimated completion is 2025-07-09.
What interventions are being tested in trial NCT06062069?
The interventions under investigation include: CT-868 (DRUG), CT-868 Pen Injector (DEVICE), CT-868 Pen Injector, Placebo (DRUG).
Who is sponsoring clinical trial NCT06062069?
This trial is sponsored by Carmot Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.